Combining the power of nature and genomics to create new medicines

Targeting Disease

Antibiotic Drug Resistance

Many bacterial infections are becoming increasingly difficult to treat as they develop resistance to currently used drugs. This impacts on healthcare systems as resistant disease is more severe, more complex to treat and often requires hospitalisation.

The loss of effective antibiotic treatments also undermines advances in other healthcare fields such as cancer therapy, complex surgery and organ or bone marrow transplants, where infection-based complications often occur.

In April 2011 the U.S. Centres for Disease Control and Prevention (CDC) estimated that antibiotic resistance costs the U.S. $20 billion a year in excess health care costs, $35 million in other societal costs and more than 8 million additional hospital days.

The acquisition of resistance to drugs is part of the process of natural evolution, hence there will always be a need for new anti-infective agents. However the number of new agents available to treat bacterial infections has been on a decline for the past 30 years.The authorities have put in place a number of measures to reinvigorate interest in antibiotic discovery, such as streamlined development pathways, priority regulatory review, extended market exclusivity and increased reimbursement. As a result companies are re-entering this important field.

Fungal Infection

Invasive fungal infections are of increasing concern due to the associated high mortality rates (often exceeding 50%) that result in 1.5 million deaths per year, costing in the order of 12 billion to treat worldwide. Treatment options are currently limited to three classes of drug, and each class has its limitations associated with pharmaceutical properties (route of administration, toxicity and drug-drug interactions) and spectrum of activity. Although not as well documented as antibiotic resistance, fungi responsible for invasive disease are becoming increasingly resistant to first and second-line treatments.

...there will always be a need for new anti-infective agents

Demuris Limited
Newcastle Biomedicine Bio-Incubators,
Faculty of Medical Sciences, Framlington Place,
Newcastle upon Tyne, NE2 4HH, UK

Tel: +44 (0)191 223 5608
Fax: +44 (0)191 223 5609
Email: enquiries@demuris.co.uk

Demuris Limited is registered in England, company number: 06255507

Demuris Limited 2015